Foster Kennedy syndrome due to meningioma growth during pregnancy

Federico Rodriguez-Porcel1, Ian Hughes2, Douglas Anderson3, John Lee2 and José Biller1*

1 Department of Neurology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA
2 Department of Pathology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA
3 Department of Neurosurgery, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA

Tumors of the olfactory groove may cause unilateral optic atrophy with contralateral papilledema and anosmia (Foster Kennedy syndrome). We describe a case of a young pregnant woman with Foster Kennedy syndrome due to an olfactory groove meningioma.

Keywords: Foster Kennedy syndrome, meningioma, pregnancy, optic disk atrophy, papilledema, anosmia

CASE PRESENTATION

A 37-year-old right handed woman from Rwanda in her 37th pregnancy week presented to our Emergency Department in labor. She was admitted to the High Risk Maternal Fetal Medicine Service. Neurology was consulted for assessment of protracted headaches of approximately 2 years duration, worsening since the first trimester of her pregnancy. In addition, visual acuity of her left eye (OS) had gradually worsened during the same period of time, resulting in complete monocular visual loss.

She had no history of nausea, vomiting, transient visual obscurations, galactorrhea, rhinorrhea, or seizures. She had no exposure to ionizing radiation or repeated cranial trauma.

On neurologic examination she had bilateral anosmia, lack of light perception OS, and visual acuity was 20/20 OD. There was a left relative afferent pupillary defect (APD). Funduscopy showed pallor of the left optic disk and blurred nasal margins of the right optic disk. Complete blood count (CBC), complete metabolic profile (CMP), thyroid stimulating hormone (TSH), prolactin, follicular stimulating hormone, luteinizing hormone (LH), and growth hormone (GH) were within the normal range expected during pregnancy. MRI of the brain without contrast showed a 3.7 cm × 3.2 cm × 1.4 cm homogeneously isointense on T1 suprasellar mass along the dural floor of the cranial fossa with compression of the left optic apex with moderate edema and no hydrocephalus. This was a significant increase from her previous MRI done a year earlier in Rwanda (Figure 1). After the first MRI she was told to come to the US to seek neurosurgical intervention.

At our institution, she received dexamethasone 4 mg every 6 h and had an uneventful delivery through a cesarean section (C-Section). Three days after C-section, a bicoronal craniotomy was done with subtotal tumor removal. A temporary lumbar drain was placed. Levetiracetam for seizure prophylaxis was given and dexamethasone taper was started on postoperative day 5. Surgical pathology showed meningioma WHO grade I, positive for progesterone receptors. The Ki-67 proliferation index overall was less than 1% (Figures 2 and 3). Following surgery, she was able to perceive light and motion with her OS.

DISCUSSION

The clinical presentation of unilateral optic atrophy with contralateral papilledema and anosmia was first fully described by Kennedy in 1911 (1). Mass lesions accounting for Foster Kennedy syndrome are frequently located in the olfactory groove, falx cerebri, sphenoid wing, or subfrontal region (2). Most masses are neoplastic, and meningiomas are the most prevalent lesions. Other reported mass lesions causing Foster Kennedy syndrome include frontal lobe abscesses, cranioopharyngiomas, pituitary adenomas, plasmacytomas, nasopharyngeal angiofibromas, neuroblastomas, and aneurysms (2). Direct compression of one optic nerve accounts for ipsilateral optic atrophy. Raised intracranial pressure (ICP) causes contralateral papilledema that usually precedes the ipsilateral optic atrophy (3) However, bilateral optic nerve compression without elevation of ICP, and chronic elevated ICP with compression have been postulated as other possible mechanisms (4). Headaches, emotional lability, memory loss, nausea, vomiting, or weakness may also be present (4). Visual changes may present as transient visual obscurations, central scotomata, unilateral or bilateral visual loss, or visual field defects (4).

Meningiomas account for 15% of all intracranial tumors, and may present as a solitary mass or as multiple masses, the latter usually associated with neurofibromatosis type 2. Most common locations of meningiomas are over the convexities of the parasagittal sphenoid ridge, olfactory groove, suprasellar/parasellar regions,
FIGURE 1 | MRI of the brain with and without contrast done in Rwanda 1 year previous to admission to our institution showed 3 cm × 2.6 cm × 1.2 cm homogeneously enhancing suprasellar mass along the dural floor of the cranial fossa.

FIGURE 2 | The specimen consists of uniform, benign-appearing, spindle-shaped cells with whorl formations containing hyalinized material with some degeneration. In time, with calcification, these whorls will progress to psammoma bodies classically observed in meningiomas.

FIGURE 3 | Progesterone receptor antibody staining, showing the presence of PR in the specimen.

tentorium cerebelli, pineal region, optic nerve, and foramen magnum (5).

Olfactory groove meningiomas (OGM) account for 8–13% of all intracranial meningiomas (5). These tumors arise in the midline of the cribriform plate and the fronto sphenoidal suture, and may extend from the crista galli to the tuberculum sellae (6). Extension may be asymmetric and may compromise the ethmoid sinuses, the nasal cavity, or even the orbit (7). OGMs receive their vascular supply primarily from the anterior and posterior ethmoidal arteries, branches of the ophthalmic artery.

Risk factors for development of meningiomas include chromosome deletion, previous ionizing therapy, and head trauma (5). The reported 2:1 female/male increases during reproductive years to 3.15:1 (8). Meningiomas may progress following contraceptive implants, during the luteal phase of the menstrual cycle, or during pregnancy (9, 10). Further studies have shown the presence of estrogen, progesterone, and androgen receptors, with progesterone receptors being present in 80% of meningiomas among women, and only 40% among men (11). However, the potential correlation of presence of hormone receptors and the natural history of meningiomas has been inconsistent.

Incidence of meningiomas in pregnancy is not different than in non-pregnant women. However, symptoms may flare up during the first two trimesters of pregnancy, with subsequent tumoral shrinkage post-partum and possible recurrence with subsequent pregnancies (12, 13). Besides the proposed influence of sexual hormones, this clinical flare-up has been attributed to water retention and engorged blood vessels (14, 15).

In pregnant patients suspected of having an intracranial mass lesion, MRI remains the preferred imaging modality because of its greater resolution, increased sensitivity, and lack of ionizing radiation. The use of gadolinium in pregnant patients controversial as gadolinium can cross the placenta, but has not been shown to cause birth defects (16, 17). CT carries the risk of ionizing radiation to the fetus, but given its greater availability, lower cost, and utility in assessing of calcifications, its use should be considered in selected circumstances and always with proper abdominal shielding (18, 19).

Management of meningiomas during pregnancy requires a multidisciplinary approach with close surveillance of mother and fetus, with delivery at term and post-partum tumor resection (20). Vaginal delivery is contraindicated in the presence of raised ICP, because cerebrospinal fluid (CSF) pressure increases with each uterine contractions during the second stage of labor (21). However, tumor resection might be warranted before delivery in patients with malignancy, active hydrocephalus requiring shunting, benign growth associated with signs of impending herniation, or progressive neurologic deficits (14). Peripartum and perioperatively edema leading to ICP can be managed with tapering doses of...
REFERENCES

1. Kennedy F. Retrobulbar neuritis as an exact diagnostic sign of certain tumors and abscesses in the frontal lobes. Am J Med Sci (1911) 142:355–68. doi:10.1097/00000441-191109000-00005

2. Lotfipour S, Chiles K, Kahn JA, Bey T, Rudkin S. An unusual presentation of subfrontal meningioma: a case report and literature review for Foster Kennedy syndrome. Intern Emerg Med (2011) 6:267–9. doi:10.1007/s11739-010-0437-y

3. Ruben S, Elston J, Hayward R. Pituitary adenoma presenting as the Foster-Kennedy syndrome. Br J Ophthalmol (1992) 76:117–9. doi:10.1136/bjo.76.2.117

4. Wallis HS, Grumbine FL, Sawhney GK, Bisner JS, Palejwala NV, Emanuel ME, et al. An aggressive sphenoid wing meningioma causing Foster Kennedy syndrome. Case Rep Ophthalmol Med (2012) 2012:102365. doi:10.1155/2012/102365

5. Nakamura M, Struck M, Roser F, Vorkapic P, Samii M. Olfactory groove meningiomas: clinical outcome and recurrence rates after tumor removal through the frontotemporal and bifrontal approach. Neurosurgery (2008) 62:1224–32. doi:10.1227/01.neu.0000333788.83349.1e

6. Bakay L, Cares HL. Olfactory meningiomas. report on a series of twenty-five cases. Acta Neurochir Rep (1972) 26(1):1–12. doi:10.1007/BF01413528

7. Adappa ND, Lee JY, Chiu AG, Palmer JN. Olfactory groove meningioma. Otolaryng Clin North Am (2011) 44(4):665–80. doi:10.1016/j.otc.2011.06.001

8. Claus EB, Black PM, Bondy ML, Calvoocressi L, Schildkrut JM, Wiemels JL, et al. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer (2007) 110(3):471–6. doi:10.1002/cncr.22783

9. Cowpilli-Bony A, Bouvier G, Ruiz M, Losseau H, Vital A, Lebaillly P, et al. Brain tumors and hormonal factors: review of the epidemiological literature. Cancer Causes Control (2011) 22(5):697–714. doi:10.1007/s10552-011-9742-7

10. Bickerstaff ER, Small JM, Guest IA. The relapsing course of certain meningiomas. J Neurol Neurosurg Psychiatry (1958) 21(2):89–91. doi:10.1136/jnnp.21.2.89

11. Vadivelu S, Sharrer L, Shultert M. Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. J Neurosurg (2010) 112:920–4. doi:10.3171/2009.8.JNS09201

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 13 September 2013; accepted: 26 October 2013; published online: 11 November 2013.

Citation: Rodríguez-Porcel F, Hughes I, Anderson D, Lee J and Biller J (2013) Foster Kennedy syndrome due to meningioma growth during pregnancy. Front. Neurol. 4:183. doi:10.3389/fneur.2013.00183

This article was submitted to Neurology Education, a section of the journal Frontiers in Neurology.

Copyright © 2013 Rodríguez-Porcel, Hughes, Anderson, Lee and Biller. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.